Baird analyst Wesley Golladay upgrades Regency Centers (NASDAQ:REG) from Neutral to Outperform and announces $71 price target.
Novavax Faces Setback, European Authority Delays Decision On Variant-Tailored COVID-19 Vaccine
Novavax Inc (NASDAQ: NVAX) faces a setback as the European Medicines Agency (EMA) delays a decision on its variant-tailored COVID-19 vaccine.